Article
Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo

https://doi.org/10.1016/0361-9230(94)00224-OGet rights and content

Abstract

Recently, a novel glial cell line-derived neurotrophic factor (GDNF) has been identified, cloned, and shown to have potent survival- and growth-promoting activity on fetal rat midbrain dopaminergic neurons in cell culture. In this study, we document marked and long-lasting effects on adult rat midbrain dopaminergic neurons in vivo after intracranial administration. A single injection of this factor into the substantia nigra elicited a dose-dependent increase in both spontaneous and amphetamine-induced motor activity, and a decrease in food consumption, lasting 7–10 days. Using immunocytochemistry, we found sprouting of tyrosine hydroxylase-positive neurites towards the injection site, and increased tyrosine hydroxylase immunoreactivity of the ipsilateral striatum was produced by GDNF. There was also a marked and dose-dependent increase in dopamine turnover in the substantia nigra and striatum, and in ipsilateral dopamine levels in the substantia nigra. Little or no effects of GDNF were seen on norepinephrine or serotonin levels. The neurochemical changes on dopaminergic afferents persist for at least 3 weeks after a single intracranial injection of 10 μg. Taken together, these data suggest that this glial cell line-derived factor has a potent influence on adult rat dopamine neurons and may have a potentially important role as a trophic factor for these neurons.

References (46)

  • A. Rousselet et al.

    Rat mesencephalic neurons in culture exhibit different morphological traits in the presence of media conditioned on mesencephalic or striatal astroglia

    Dev. Biol.

    (1988)
  • I. Strömberg et al.

    Glial cell line-derived neurotrophic factor (GDNF) is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo

    Exp. Neurol.

    (1993)
  • M.J. Zigmond et al.

    Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications

    Int. Rev. Neurobiol.

    (1989)
  • C. Altar et al.

    Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo

  • E.-O. Backlund et al.

    Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials

    J. Neurosurg.

    (1985)
  • M.C. Bohn et al.

    Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers

    Science

    (1987)
  • T. Collier et al.

    Diffusible factor(s) from adult rat sciatic nerve increases cell number and neurite outgrowth of cultured embryonic ventral mesencephalic tyrosine hydroxylase-positive neurons

    J. Neurosci. Res.

    (1990)
  • R. Dal Toso et al.

    Development and survival of neurons in dissociated fetal mesencephalic serum-free cell cultures: I. Effects of cell density and of an adult mammalian striatal-derived neuronotrophic factor (SDNE)

    J. Neurosci.

    (1988)
  • J. Engele et al.

    Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: Role of mesencephalic glia

    J. Neurosci. Res.

    (1991)
  • G. Ferrari et al.

    Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: Comparison with basic fibroblast growth factor

    J. Neurosci. Res.

    (1991)
  • G. Gaul et al.

    Cortical astrocytes activated by basic fibroblast growth factor secrete molecules that stimulate differentiation of mesencephalic dopaminergic neurons

  • D. German et al.

    Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells

    Ann. NY Acad. Sci.

    (1992)
  • A. Goodman-Gilman et al.

    The pharmacological basis of therapeutics

    (1990)
  • Cited by (212)

    • Update of neurotrophic factors in neurobiology of addiction and future directions

      2017, Neurobiology of Disease
      Citation Excerpt :

      Both GDNF and NRTN can protect and restore the nigrostriatal dopamine circuitry in animal models of PD, and they have been tested in human clinical trials for PD, with variable and mainly disappointing results (Rangasamy et al. 2010). In the intact rodent brain, GDNF boosts the dopaminergic function by increasing dopamine turnover, augmenting stimulus-induced dopamine release, as well as inducing sprouting of tyrosine hydroxylase-reactive fibers (Cass et al. 1999; Hebert et al. 1996; Hudson et al. 1995). Although the most intriguing effect of BDNF in the intact CNS may be its role in regulating long term potentiation (LTP) (Kang and Schuman 1995; Lohof et al. 1993), infusion of BDNF into intact rat brain also increases dopamine turnover, induces contralateral rotations after amphetamine administration, and affects the firing rate and number of spontaneously active dopamine neurons (Altar et al. 1992; Shen et al. 1994).

    View all citing articles on Scopus
    View full text